Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on November 18, 2008, covering events that occurred on November 14, 2008. The filing primarily addresses executive leadership changes within the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on personnel appointments rather than financial performance data.
Material Changes
- Appointment of CFO: Thomas McNaughton, Jr. was appointed as Chief Financial Officer and Principal Accounting Officer, effective November 14, 2008.
- Departure of Principal Officer: Susan Luscinski was replaced as Principal Accounting Officer by Mr. McNaughton.
- Employment Agreement: An employment agreement was entered into with Mr. McNaughton with an effective date of December 15, 2008.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding business strategy. It details the terms of the new CFO's employment agreement:
- Term: Initial one-year term with automatic annual extensions unless 90 days' notice is given.
- Compensation: Initial base salary of $235,000, subject to annual review by the Compensation Committee, plus incentive compensation.
- Termination Provisions: In cases of termination without cause or for good reason, the executive is eligible for up to one year's salary and bonus, one year of benefit extension, and acceleration of vesting for stock options and restricted stock vesting within the next 12 months.
- Change of Control: Triggers payment of up to one year's salary and bonus, one year of benefit extension, and acceleration of vesting for all outstanding equity awards.
- Restrictions: Includes a 12-month non-compete and non-solicitation clause following termination.
Investor Verification Checklist
- Verify the effective date of the new CFO's employment (December 15, 2008) versus the appointment date.
- Confirm the specific vesting schedules for existing stock options and restricted stock to understand the acceleration triggers.
- Review the definition of "good reason" and "change of control" in the attached employment agreement (Exhibit 10.1) to assess potential liability.
- Check subsequent filings for the departure details of the former Principal Accounting Officer, Susan Luscinski.